$16.89
+0.69(4.26%)
Mkt Cap $183M
$15.05
$22.24
52-Week Range
At a Glance
AI-generated6-K
MediWound announced Vericel, its exclusive North America distributor, received a BARDA contract valued at up to $197 million for NexoBrid procurement, manufacturing, and development over ten years.$183M
Market Cap
$14M
Revenue
-$20M
Net Income
Employees111
Fundamentals
How The Business Makes Money
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001593984
ISINIL0011316309
CUSIPM68830104
Phone972 7 797 14100
Address42 Hayarkon Street, Yavne, 8122745, IL
SEC EDGAR